Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitor AB801. (October 2022) - Miles, D.; Paprcka, S.; Foley, C.; Qu, S.; Lamani, M.; Paladugu, S.; Huang, H.T.; Tibrewal, N.; Chen, A.; Kulusich, J.; Garrido-Shaqfeh, S.; Fabila, P.; et al.